M. Sasane

发表

Patient-Reported Outcomes in Chemotherapy-Induced Peripheral Neuropathy: A Review

K. Beusterien, T. Tencer, M. Sasané, 2010 .

Progression-free survival and quality of life in metastatic breast cancer: The patient perspective

F. Cardoso, S. May, Kyi-Sin Than, 2022, Breast.

Characteristics, treatment patterns, and survival among ALK+ non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review study.

Keunchil Park, O. Arrieta, E. Swallow, 2016, Lung cancer.

Adherence to iron chelation therapy and associated healthcare resource utilization and costs in Medicaid patients with sickle cell disease and thalassemia

Y. Qiu, F. Vekeman, A. Ramanakumar, 2016, Journal of medical economics.

Long-term persistency and costs associated with the use of iron chelation therapies in the treatment of Sickle cell disease within Medicaid programs

E. Armstrong, G. Skrepnek, S. Ballas, 2013, Journal of medical economics.

1 As submitted to : Journal of Medical Economics And later published as : Long-Term Persistency and Costs Associated with the Use of Iron Chelation Therapies in the Treatment of Sickle Cell Disease within Medicaid Programs in the United States

E. Armstrong, G. Skrepnek, S. Ballas, 2017 .

Adjuvant endocrine therapy uptake, toxicity, quality of life, and prediction of early discontinuation.

C. Coulouvrat, C. Coutant, M. Campone, 2023, Journal of the National Cancer Institute.

Comparison of Different Adjuvant Therapies for 9 Resectable Cancer Types

J. Coombs, Douglas C. A. Taylor, A. Parthan, 2013, Postgraduate medicine.

F. Vekeman, M. Duh, C. Paley, 2015, The Journal of emergency medicine.

Resource Utilization Associated with Irritable Bowel Syndrome in the United States: 1987–1997

P. Jhingran, R. Sandler, M. Halpern, 2002, Digestive Diseases and Sciences.

Qualitative Patient Interviews to Characterize the Human Burden of Advanced Basal Cell Carcinoma Following Hedgehog Pathway Inhibitor Treatment

T. Symonds, J. Randall, D. Rofail, 2023, Dermatology and Therapy.

Brain metastases in patients with ALK+ non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden

E. Wu, R. Nitulescu, K. Dea, 2015, Journal of medical economics.

Multicenter COMPACT study of COMplications in Patients with sickle cell disease And utilization of iron Chelation Therapy

C. Bieri, F. Vekeman, M. Duh, 2015, Current medical research and opinion.

F. Vekeman, M. Duh, C. Paley, 2013, Pediatric blood & cancer.

Treatment Patterns and Early Outcomes of ALK-Positive Non-Small Cell Lung Cancer Patients Receiving Ceritinib: A Chart Review Study

Anand A. Dalal, A. Macalalad, K. Culver, 2017, Advances in Therapy.

ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer.

H. Wakelee, E. Wu, A. Macalalad, 2015, Cancer epidemiology.

Treatment Patterns, Prescribing Decision Drivers, and Predictors of Complete Response Following Disease Recurrence in Gastrointestinal Stromal Tumor Patients—a Chart Extract-Based Approach

C. Keir, E. Wu, A. Guérin, 2014, Journal of Gastrointestinal Cancer.

Parents' decision-making regarding vaccinating their children against influenza: A web-based survey.

K. Beusterien, S. Block, E. Flood, 2010, Clinical therapeutics.

The economic burden of brain metastasis among lung cancer patients in the United States

J. Zhang, E. Wu, R. Nitulescu, 2016, Journal of medical economics.

Pharmacoeconomic Considerations in Treating Iron Overload in Patients with β-Thalassaemia, Sickle Cell Disease and Myelodysplastic Syndromes in the US

C. Pashos, Bin Zhang, M. Corral, 2011, PharmacoEconomics.

CASE (CemiplimAb-rwlc Survivorship and Epidemiology) study in advanced cutaneous squamous cell carcinoma.

S. Ibrahim, S. Chandra, M. Migden, 2020, Future oncology.

Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer.

Anand A. Dalal, N. Myall, H. Wakelee, 2019, Lung cancer.

Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United States

J. Coombs, Douglas C. A. Taylor, M. Sanon, 2013, Journal of medical economics.

Physician Underestimation of the Risk of Gastrointestinal Stromal Tumor Recurrence After Resection.

C. Keir, E. Wu, A. Macalalad, 2015, JAMA oncology.

Assessing the Value of Cemiplimab for Adults With Advanced Cutaneous Squamous Cell Carcinoma: A Cost-Effectiveness Analysis.

D. Ayers, N. Khushalani, S. Keeping, 2021, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Comparison of the Long-Term Risk of Recurrence and Other Clinical Outcomes in GIST Patients Receiving Imatinib as Adjuvant Therapy—A Retrospective Chart Extract-Based Approach

C. Keir, E. Wu, A. Guérin, 2012, Journal of Gastrointestinal Cancer.

Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis

A. Hauschild, D. Schadendorf, I. Lowy, 2021, Journal for ImmunoTherapy of Cancer.

Cost-effectiveness analysis of cemiplimab vs pembrolizumab for treatment of advanced cutaneous squamous cell carcinoma

D. Ayers, P. Guyot, S. Keeping, 2021, Journal of managed care & specialty pharmacy.

Comparative Efficacy of Treatments for Previously Treated Advanced or Metastatic Non-Small-Cell Lung Cancer: A Network Meta-Analysis

Jinrong Zhao, Junlong Li, Zheng-Yi Zhou, 2018, Advances in Therapy.

Economic impact on US Medicare of a new diagnosis of myelodysplastic syndromes and the incremental costs associated with blood transfusion need

M. Laouri, E. Chen, S. Goldberg, 2012, Transfusion.

Impact of underestimation of risk on treatment duration and recurrence in GIST patients.

C. Keir, E. Wu, A. Macalalad, 2014 .

Effectiveness of adjuvant imatinib in patients with gastrointestinal stromal tumor: results of a population-based, matched-cohort study

Swu-Jane Lin, J. Trent, H. Hatoum, 2012, Current medical research and opinion.

Treatment, overall survival, and costs in patients with ALK-positive non-small-cell lung cancer after crizotinib monotherapy

H. Wakelee, R. Nitulescu, A. Macalalad, 2015, Current medical research and opinion.

Patient‐reported outcomes with cemiplimab monotherapy for first‐line treatment of advanced non–small cell lung cancer with PD‐L1 of ≥50%: The EMPOWER‐Lung 1 study

I. Bondarenko, C. Ivanescu, V. Mastey, 2022, Cancer.

Monitoring for and Characterizing Crizotinib Progression: A Chart Review of ALK-Positive Non-Small Cell Lung Cancer Patients

Anand A. Dalal, A. Macalalad, A. Guérin, 2017, Advances in Therapy.

Is time to progression associated with post-progression survival in previously treated metastatic non-small cell lung cancer with BRAF V600E mutation? A secondary analysis of phase II clinical trial data

Junlong Li, Jing Zhao, J. Signorovitch, 2018, BMJ Open.

Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes.

E. Friedmann, S. Gore, M. Baer, 2015, Journal of comparative effectiveness research.

Medical complications, resource utilization and costs in patients with myelofibrosis by frequency of blood transfusion and iron chelation therapy

R. Mesa, F. Vekeman, M. Duh, 2015, Leukemia & lymphoma.

Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma.

C. Schmults, E. Stockfleth, D. Ayers, 2020, Future oncology.

Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United States

J. Coombs, Douglas C. A. Taylor, M. Sanon, 2013, Journal of medical economics.

Epidemiologic and clinical characteristics of nontransfusion‐dependent thalassemia in the United States

E. Vichinsky, Y. Qiu, A. Thompson, 2018, Pediatric blood & cancer.

Economic Impact of Next-Generation Sequencing Versus Single-Gene Testing to Detect Genomic Alterations in Metastatic Non-Small-Cell Lung Cancer Using a Decision Analytic Model.

Anand A. Dalal, G. Otterson, N. Pennell, 2019, JCO precision oncology.

Characteristics, treatment patterns, and survival among ALK+ non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review study.

Keunchil Park, O. Arrieta, E. Swallow, 2016, Lung cancer.

Long-term persistency and costs associated with the use of iron chelation therapies in the treatment of Sickle cell disease within Medicaid programs

E. Armstrong, G. Skrepnek, S. Ballas, 2013, Journal of medical economics.